Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-071635
Filing Date
2025-05-14
Accepted
2025-05-14 17:29:35
Documents
80
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ikt-20250331.htm   iXBRL 10-Q 1544667
2 EX-31.1 ikt-ex31_1.htm EX-31.1 14955
3 EX-31.2 ikt-ex31_2.htm EX-31.2 15028
4 EX-32.1 ikt-ex32_1.htm EX-32.1 11938
5 EX-32.2 ikt-ex32_2.htm EX-32.2 11949
  Complete submission text file 0000950170-25-071635.txt   7535181

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ikt-20250331.xsd EX-101.SCH 1241197
83 EXTRACTED XBRL INSTANCE DOCUMENT ikt-20250331_htm.xml XML 1247215
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39676 | Film No.: 25947283
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)